Cowen & Co
http://www.cowen.com/default.htmlCowen and Company offers investment banking services, including equity research, equity and convertible debt financings, mergers and acquisitions advisory services, and restricted security sales.
View Older Stories
-
TD Cowen Reiterates Buy Rating on CVS Health (CVS)
-
Adobe (ADBE) PT Lowered to $310 at TD Cowen
-
Xenon Pharmaceuticals closes $747.5 million public offering
-
Dianthus Therapeutics completes $719 million public offering
-
TD Cowen: 'We est ~+3%/+2%/ +2%/+1% EBITDA pickup for HCA/UHS/THC/ACHC'
-
TD Cowen Reiterates Buy Rating on MBX Biosciences Inc (MBX): "confident" that canvu Phase III will be successful
-
TD Cowen's Europe Best Ideas: Marex Group PLC (MRX)
-
TD Cowen Highlights Nanobiotix S.A (NBTX) as 'Europe Best Ideas'
-
TD Cowen on Home Depot (HD): 'Expertly Playing Offense Despite A Tougher Macro'
-
biote Corp. (BTMD) PT Lowered to $2.50 at TD Cowen
-
Kodiak AI (KDK) PT Lowered to $13 at TD Cowen
-
Campbell Soup (CPB) PT Lowered to $24 at TD Cowen Amid 'Further Pricing Pressure'
-
TD Cowen Reiterates Buy Rating on EPAM Systems (EPAM) amid guidance affirmation
-
This 'key beneficiary of AI infrastructure' is a new Top Pick at TD Cowen
-
TD Cowen Reiterates Buy Rating on Netskope (NTSK)
-
TD Cowen Starts BWX Technologies (BWXT) at Buy
-
UiPath Inc. (PATH) PT Lowered to $13 at TD Cowen
-
TD Cowen Reiterates Buy Rating on Uber Inc. (UBER)
-
TD Cowen on Oracle (ORCL): 'We see this print as a turning point for the stock'
-
TD Cowen Reiterates Hold Rating on Campbell Soup (CPB), 'will suspend share repurchases given elevated leverage at 3.8x'
-
Starboard nominates directors to CarMax board
-
Goeasy Ltd (GSY:CN) (EHMEF) PT Lowered to Cdn$44 at TD Cowen
-
Dianthus Therapeutics prices $625 million public stock offering
-
Xenon Pharmaceuticals prices $650 million stock offering at $57 per share
-
Medline completes $3.5 billion secondary stock offering
-
Rivian stock jumps 5% as TD Cowen upgrades to buy ahead of R2 launch
-
Novo Nordisk downgraded as pipeline 'not poised to blunt semaglutide LOE'
-
TD Cowen Reiterates Buy Rating on Protara Therapeutics (TARA): "encouraged by Q4 operational update"
-
TD Cowen Highlights Universal Music Group NV (UMG:NA) (UMGNF) as 'Europe Best Ideas'
-
TD Cowen on Planet Fitness (PLNT): 'CFO Transition Should Accelerate Progress On Strategic Initiatives'
-
Adobe (ADBE) PT Lowered at TD Cowen Amid 'Continued Growth Deceleration'
-
Chewy Inc. (CHWY) PT Lowered to $39 at TD Cowen
-
HCA Healthcare Inc (HCA) PT Raised to $561 at TD Cowen
-
TD Cowen: 'ASML Holding NV (ASML:NA) (ASML) Remains Our Best European Idea in 2026'
-
Infineon Technologies AG (IFX:GR) (IFNNY) PT Raised to EUR54 at TD Cowen
-
Corebridge Financial (CRBG) PT Lowered to $35 at TD Cowen
-
TD Cowen Upgrades Rivian Automotive Inc (RIVN) to Buy 'following Our R2 Demand Deep-Dive & New AOTC Report'
-
TD Cowen Downgrades Novo Nordisk (NVO) to Hold
-
USA Rare Earth names three senior executives to leadership team
-
TD Cowen Reiterates Buy Rating on Jade Biosciences (JBIO): "potential best-in-class"
-
Dianthus Therapeutics announces $400 million public stock offering
-
Xenon Pharmaceuticals announces $500 million public offering
-
TD Cowen Reiterates Buy Rating on Benitec BioPharma (BNTC): "strong POC to support Ph3 success"
-
TD Cowen: 'Wegovy Injection may be declining'
-
TD Cowen Reiterates Buy Rating on Editas Medicine (EDIT) following Q4 results
-
TD Cowen Reiterates Buy Rating on Dianthus Therapeutics (DNTH): "prime takeout target"
-
TD Cowen on Olema Pharmaceuticals (OLMA): 'Pala's Profile And Data Support Phase IIIs, Despite persevERA Disappointment'
-
TD Cowen on United Therapeutics Corp. (UTHR) Buyback: 'We believe that this signals management's confidence'
-
TD Cowen Reiterates Buy Rating on Regeneron Pharma (REGN): "if results are replicated in US, could lead to preferential prescribing"
-
TD Cowen Reiterates Buy Rating on Rapport Therapeutics (RAPP): strategic collab with Tenacia "a prudent move"

